Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, multicenter, observational cohort study to collect data on Chilean patients diagnosed with Heart Failure with reduced ejection fraction, their treatments, and their progress in a real-world environment. Additional objectives will be analyzed, such as mortality, and the barriers, if any, to receiving the indicated treatment.
Identify the main epidemiological and clinical characteristics of patients with Heart Failure with reduced ejection fraction, as well as the medical treatment models used.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Identify the main epidemiological and clinical characteristics of patients with Heart Failure with reduced ejection fraction, as well as the medical treatment models used. | Patient´s baseline characteristics, medical history, socio-economic data, ancillary studies, laboratory tests, and cardiovascular medication will be summarized using summary statistics. Continuous variables will be presented using mean, standard deviation (SD), minimum, median, maximum, and interquartile range (IQR). Categorical variables will be presented as frequency and percentage. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Determine the prescription rate of a cardiovascular pharmacological treatment in patients with Heart Failure with reduced ejection fraction | Percentage of cardiovascular medication prescription by type | 1 year |
| Determine the prescription rate of a cardiac medical device in patients with Heart Failure with reduced ejection fraction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Chilean patients diagnosed with Heart Failure with reduced ejection fraction, regardless of the time of disease progression.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudio Muratore, MD | Medtronic | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Clínico Regional Guillermo Grant Benavente | Concepción | Chile | ||||
| Hospital Clínico Pontificia Universidad Católica de Chile |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Percentage of patients with an indication for a cardiac medical device. |
| 1 year |
| Determine the implant rate of a cardiac medical device in patients with Heart Failure with reduced ejection fraction | Percentage of patients implanted with a cardiac medical device. | 1 year |
| Determine the mortality rate and its classification in patients with Heart Failure with reduced ejection fraction during a 12-month period. | Percentage of deaths during the study follow-up period Number and percentage of deaths according to their classification. Risk assessment of sudden cardiac death in the population. Risks comparison of sudden death at 6 and 12 months of follow-up | 1 year |
| Determine the hospitalization rate for heart failure during the 12-month follow-up. | Percentage of Hospitalizations during the study follow-up period. | 1 year |
| Identify the barriers, if any, to prescribing and implanting a cardiac medical device in those patients with a Class I recommendation according to the ACC/AHA/HRS 2017 guidelines. | Percentage of reasons for not indicating a cardiac medical device. Number and percentage of reasons for not implanting a cardiac medical device | 1 year |
| Determine the population with a profile of 1.5 primary prevention of sudden cardiac death | Frequency of patients with indication for 1.5 primary prevention of sudden cardiac death (patients with Heart Failure in primary prevention who have one or more of the following risk factors: syncope or pre-syncope; left ventricular ejection fraction less than 25%; presence of non-sustained ventricular tachycardia; more than 10 ventricular extrasystoles per hour observed in a 24-hour Holter) | 1 year |
| Santiago |
| Chile |
| Hospital San Juan de Dios | Santiago | Chile |
| Hospital Talagante | Santiago | Chile |
| Hospital Hernan Henriquez Aravena | Temuco | Chile |
| Hospital Dr. Gustavo Fricke | Viña del Mar | Chile |